Literature DB >> 7839360

Relationship between glutathione concentration and metabolism of the pyrrolizidine alkaloid, monocrotaline, in the isolated, perfused liver.

C C Yan1, R J Huxtable.   

Abstract

The influence of GSH concentration on metabolism of monocrotaline was examined in the isolated, perfused rat liver. Chloroethanol (0.37 mmol/kg), diethyl maleate (5.6 mmol/kg), and buthionine sulfoximine (72.9 mmol/kg) given in vivo reduced hepatic GSH from 3.7 mumol/g wet weight to 1.5, 0.6 and 0.9 mumol/g, respectively. Livers were then perfused in vitro for 1 hr with monocrotaline (0.5 mM). GSH depletion had no effect on the total release of pyrrolic metabolites of monocrotaline. Depletion, however, markedly affected the pattern of pyrrole release. Biliary release of 7-glutathionyl-6,7-dihydro-1-hydroxy-methyl-5H-pyrrolizine (GSDHP) was reduced by up to 72%. Pretreatment with diethyl maleate or buthionine sulfoximine increased the level of protein-bound pyrroles in the liver by 107 and 84%, respectively. Such pyrroles are probably responsible for liver toxicity. GSH depletion also led to a doubling of dehydromonocrotaline release into the perfusate. This metabolite is probably responsible for the extrahepatic toxicity of monocrotaline. Release into perfusate of the relatively nontoxic metabolite, 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP) was correspondingly decreased. Hepatic GSH content was increased to 4.4 mumol/g by pretreatment with oxo-4-thiazolidine carboxylate (4.76 mmol/kg). This agent increased total pyrrolic metabolites by 54%. Biliary release of GSDHP and perfusate release of dehydromonocrotaline and DHP were all increased. Thus, hepatic GSH levels regulate the metabolism of monocrotaline and dehydromonocrotaline and, consequently, the hepatic and extrahepatic toxicity of monocrotaline. GSH depletion leads to a switch from the biliary release of the midly toxic GSDHP to the perfusate release of the highly toxic dehydromonocrotaline. GSH depletion also permits more dehydromonocrotaline in the liver to become available for macromolecular alkylation. These findings suggest that nutritional intake of sulfur-containing amino acids can influence the severity of pyrrolizidine poisoning.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7839360     DOI: 10.1006/taap.1995.1017

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

1.  Physicochemical and metabolic basis for the differing neurotoxicity of the pyrrolizidine alkaloids, trichodesmine and monocrotaline.

Authors:  R J Huxtable; C C Yan; S Wild; S Maxwell; R Cooper
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

2.  Metabolomic and genomic evidence for compromised bile acid homeostasis by senecionine, a hepatotoxic pyrrolizidine alkaloid.

Authors:  Aizhen Xiong; Fan Yang; Lianxiang Fang; Li Yang; Yuqi He; Yu-Jui Yvonne Wan; Yvonne Yu-Jui Wan; Ying Xu; Meng Qi; Xiuli Wang; Kate Yu; Karl Wah-Keung Tsim; Zhengtao Wang
Journal:  Chem Res Toxicol       Date:  2014-04-01       Impact factor: 3.739

3.  The protective effects of cerium oxide nanoparticles against hepatic oxidative damage induced by monocrotaline.

Authors:  Kamal A Amin; Mohamed S Hassan; El-Said T Awad; Khalid S Hashem
Journal:  Int J Nanomedicine       Date:  2011-01-17

4.  Pyrrolizidine Alkaloid-Induced Hepatotoxicity Associated with the Formation of Reactive Metabolite-Derived Pyrrole-Protein Adducts.

Authors:  Jiang Ma; Mi Li; Na Li; Wood Yee Chan; Ge Lin
Journal:  Toxins (Basel)       Date:  2021-10-13       Impact factor: 4.546

5.  Synthesis and phototoxicity of isomeric 7,9-diglutathione pyrrole adducts: Formation of reactive oxygen species and induction of lipid peroxidation.

Authors:  Liang Ma; Hengqiang Zhao; Qingsu Xia; Lining Cai; Peter P Fu
Journal:  J Food Drug Anal       Date:  2015-07-02       Impact factor: 6.157

Review 6.  Pyrrole-protein adducts - A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity.

Authors:  Jiang Ma; Qingsu Xia; Peter P Fu; Ge Lin
Journal:  J Food Drug Anal       Date:  2018-06-14       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.